### **up**

**We are an Israeli group of two SMEs (**[**Genoox**](https://www.genoox.com/) **and** [**Ibex Medical Analytics**](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/org-details/897849267;searchKeyword=;searchTopic=;searchTopicName=;call=;searchProgramme=;searchProgrammeName=null;legalName=Ibex;organisationType=;country=;city=;pic=;countryAbbreviation=)**) and a scientific research Institute (**[**IMBM**](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/org-details/997851126;searchKeyword=;searchTopic=;searchTopicName=;call=;searchProgramme=null;searchProgrammeName=null;legalName=IMBM;organisationType=;country=;city=;pic=)**) setting up (or wishing to join ) a consortium for submission to IMI under call topic** [**IMI2-2020-23-04 – "Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence.**](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/imi2-2020-23-04;freeTextSearchKeyword=imi;typeCodes=0,1;statusCodes=31094501,31094502,31094503;programCode=null;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=Default;sortQuery=submissionStatus;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState)"

Our project, **CARDYNAL (CAncer Rationalized by a DYNamic AI modeL)**,will focus on integrating genomic and clinical data, as well as pathology imaging data, within dynamic-mechanistic mathematical models capturing longitudinal tumor evolvement, as an intertwined AI-based framework (e.g., a medical software device) for predicting patient response and personalizing/optimizing patient treatment and care in advanced lung, prostate, and breast cancers.

We are looking for the following groups to partner with us:

* **An official Coordinator** (entity with strong administrative capacity, preferably experienced as coordinators)
* **Medical Oncology groups and opinion leaders** with expertise in Lung, Prostate, and Breast Cancer
* **Clinical & research organizations providing data**: Medical centers allowing access to real-world patient data, EHRs and clinical trial databases
* **Biotechnology companies/SMEs** with expertise in IT system design, user experience design and accessibility, user interface, etc.
* **Data platform companies** with expertise in data management and security
* **Patient organizations and Regulatory bodies** with expertise on data privacy and ownership

**About** [**IMBM**](https://www.imbm.org/)

**IMBM** delves in the area of precision medicine, designing software algorithms for optimizing and personalizing cancer drug therapy in advanced cancers. Our technology relies on mechanistic mathematical modeling of disease dynamics together with statistical/AI models. It enables unique integration of multiscale patient information (e.g. genomics, proteomics, tumor biomarkers, radiology assessments, and clinical metrics).

Our algorithms enable to predict personal patient response to therapy, surface prognostic/predictive biomarkers, prioritize various therapeutic options in a guideline-compliant manner, and assist physician's decision-making, to extend patient's survival and QoL.

With its interdisciplinary team, IMBM has been active in research, industry and pharma-oriented projects in personalized oncology, partly under its associated startup [Optimata Ltd.](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/org-details/986163596;searchKeyword=;searchTopic=;searchTopicName=;call=;searchProgramme=;searchProgrammeName=null;legalName=optimata;organisationType=;country=;city=;pic=;countryAbbreviation=) (publications appear [here](https://www.imbm.org/section-labelteam-sorted-hero-bg20-bg_overlayrgba000-5-bg_pos47-65-darktrue-padding90px-scroll_for_moretrue-row-col-span6-span__sm12-span__md/) and [here](https://www.optimata.com/publications)). We have headed and participated in many EU-funded projects ([DDmore](https://cordis.europa.eu/project/id/115156%22%20%5Co%20%22https%3A//cordis.europa.eu/project/id/115156) under IMI JU, as well as [COLOSSUS](https://cordis.europa.eu/project/id/754923), [MEL-PLEX](https://cordis.europa.eu/project/id/642295), [APODECIDE](https://cordis.europa.eu/project/id/306021), [NEST](https://cordis.europa.eu/project/id/12930), etc.).

**About** [**Ibex Medical Analytics**](https://ibex-ai.com/)

**Ibex** develops AI-based cancer diagnostics in pathology labs and prognostic & predictive algorithms for the personalization of cancer treatment. Ibex deployed the first-ever AI-based pathology diagnosis system under the Galen™ Platform in a live clinical setting for prostate & breast biopsies, providing invaluable field experience in the analysis of real-world clinical data.

Ibex applies AI and deep learning to pathology reports and images, and combines other clinical data to further improve on risk stratification and treatment response. Our unique AI approach and multi-disciplinary expertise enables rapid implementation of our solutions due to a holistic understanding of the ecosystem, key for success in healthcare. Ibex solution for prostate biopsies is CE-IVD certified and clinically deployed globally, and for breast biopsies is deployed in Israel (in course of CE-IVD certification). Ibex participates in EU projects in prostate cancer (ReIMAGINE) and other projects on AI markers for drug response.

Ibex was selected to be a part of Digital Health London and was featured as one of Nanalyze 7 AI cancer diagnostics startups digitizing healthcare.

**About** [**Genoox**](https://www.genoox.com/)

**Genoox** is a Healthcare Technology SME developing an AI-based interpretation engine for genomic data, which already supports decision making for cancer patients based on their genomics and clinical background. In addition to prioritization of genetic markers, the platform provides the entire evidence including relevant clinical trials and drugs, and aligns with NCCN guidelines. The engine also prioritizes variants according to the AMP, ASCO, CAP Guidelines in a tiered classification system. AI and NLP methods are used to extract evidence also from unstructured data sources including scientific publications.

The Genoox platform is being used by hundreds of organizations around the world for genetic interpretation based on panels, exomes and genomes for various cancer cases. Our team includes skilled bioinformaticians, data scientists, software engineers, geneticists and clinicians. The platform’s [community edition](https://franklin.genoox.com/) can give a sense of what we excel at. We are in the top 5 startups disrupting healthcare with AI (Business Insider) and Customer Value Leadership award for Genetic Analysis Market by Frost & Sullivan.

**To express your interest please fill out the following form and send to one or more of the following contacts no later than August 31st 2020:**

Prof. Zvia Agur, President | **Institute for Medical BioMathematics (IMBM)** | agur@imbm.org

Dr. Moshe Einhorn, Chief Technology Officer | **Genoox** | moshe@genoox.com

Dr. Manuela Vecsler, Scientific & Clinical Affairs Manager | **Ibex Medical Analytics** | manuela.vecsler@ibex-ai.com

**Organization Name:**

**Organization type (e.g. Academia, research institute, SME, etc.):**

**Contact name:**

**Role:**

**Mail:**

**Telephone (include international prefix):**

**Link to your organization website:**

**Links to previously EU funded projects websites you took part in and a Description of your role and capacities in these projects:**

**Your organization PIC number in the Funding and Tenders portal:**

**Describe your expertise in context with the call topic text:**

**Describe any additional contribution to the consortium (e.g. your proposal writing skills, administrative capacities, additional partners you may bring with you, etc.):**